Thursday, May 22, 2014

CD44 labelled PEG-PLGA for ovarian cancer treatment

PolySciTech ( provides a wide variety of PEG-PLGA copolymers including PLGA-PEG-Maleimide similar to that used in a recent study to create CD44 labelled nanoparticles for targeted drug delivery to ovarian cancer cells. Read more: Bai, Meng-Yi, and Sheng-Zhong Liu. "A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: An in vitro study of targeted delivery of cisplatin to ovarian cancer cells." Colloids and Surfaces B: Biointerfaces 117 (2014): 346-353.
“Abstract: Cisplatin-encapsulating maleimide-polyethylene glycol- Poly(d,l-lactic-co-glycolide) (cis-encapsulating mal-PEG-PLGA) particles were produced using the electrospray technique and bioconjugated with CD44 monoclonal antibody, targeting the counterpart receptor. The produced suspension of cis-encapsulating CD44-PEG-PLGA particles contains an antibody loading of 12.65–15.17 μg/mL and efficiently targets a CD44-overexpressed ovarian cancer cell line, such as CP70 and SKOV-3, within 6 h of treatment, which was determined by Bradford assay, immunofluorescence analysis, and confocal laser scanning microscopic (CLSM) study. Most importantly, no tedious multi-step bioconjugation procedures are needed to synthesize mal-PEG-PLGA vehicles for antibody and drug loading, avoiding the undesirable hydrolysis of mal-PEG moiety and so successfully generating the cis-encapsulating mal-PEG-PLGA particles within one step. After conjugation of the CD44 antibody, the produced cis-encapsulating CD44-PEG-PLGA particles exhibited a better anti-proliferative ability against ovarian cancer cells compared to free form of cisplatin and PLGA particles without CD44 conjugation. Notably, the cis-encapsulating CD44-PEG-PLGA particles have approximately 10-14% greater the anti-proliferative ability against CP70 and SKOV-3 cells at a concentration of 1.25 μM, which falls within the concentrations used in chemotherapy. The proposed antibody-functionalization strategy represents an excellent platform for preparing particles with targeting ability in cancer therapy in vitro or in vivo. Highlights: We report a simple method for preparing antibody-PEG-PLGA particles using electrospray. Particles were produced using the electrospray system and bioconjugated with CD44 antibody. The cis-encapsulating CD44-PEG-PLGA particles contain an antibody loading of 12.65–15.17 μg/mL. The cis-encapsulating CD44-PEG-PLGA particles against CP70 and SKOV-3 cells were improved by 10–14%. Keywords Electrospray; Nanotechnology; Controlled release; Drug delivery; Biomaterials.”

Post a Comment